natgillin/translations-raw huggingface dataset:
A 10.5 mg/kg (0.105 ml/kg) loading dose is recommended on the first day of treatment with levetiracetam.
Prvi dan zdravljenja z levetiracetamom je priporočljiv začetni odmerek 10,5 mg/kg (0,105 ml/kg).
• 1000 mg: 10, 20, 30, 50, 60, 100 and multipack of 200 (2 packs of 100) film-coated tablets.
• 1000 mg: 10, 20, 30, 50, 60, 100 ali skupno pakiranje po 200 (2 pakiranji po 100) filmsko obloženih tablet.
• 500 mg: 10, 20, 30, 50, 60, 100, 120 and multipack of 200 (2 packs of 100) film-coated tablets.
• 500 mg: 10, 20, 30, 50, 60, 100, 120 ali skupno pakiranje po 200 (2 pakiranji po 100) filmsko obloženih tablet.
Matever 250 mg film-coated tablets levetiracetam2.
Matever 250 mg filmsko obložene tablete levetiracetam
− This medicine has been prescribed for you only.
Zdravilo je bilo predpisano vam osebno in ga ne smete dajati drugim.
Coating agent (orange) consisting of: Hypromellose (E464) Indigo carmine aluminum lake (E132) Sunset yellow FCF aluminum lake (E110) Iron oxide red (E172) Macrogol/PEG 4000
Obloga (oranžna), ki jo sestavljajo: hipromeloza (E464), indigotin (E132), sončno rumeno FCF (E110), rdeči železov oksid (E172), makrogol 4000, titanov dioksid (E171).
Levetiracetam 100mg/ml oral solution is a formulation more appropriate to infants and children under the age of 6 years and to children and adolescents (from 6 to 17 years) weighing less than 50 kg and when tablets don't allow accurate dose.
Za dojenčke in otroke, mlajše od 6 let, otroke in mladostnike (od 6 do 17 let), lažje od 50 kg, ter kadar se s tabletami ne doseže natančnega odmerjanja, je 100 mg/ml peroralna raztopina levetiracetama primernejša farmacevtska oblika.
Rhabdomyolysis and blood creatine phosphokinase increased*
Splošne težave in spremembe na mestu aplikacije astenija/utrujenost rabdomioliza in zvišanje kreatin fosfokinaze v krvi*
How to store Matever
Kako se daje zdravilo Matever
Matever 500 mg film-coated tablets levetiracetam2.
Matever 500 mg filmsko obložene tablete levetiracetam
Toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme
Johnsonov sindrom, multiformni eritem
Component of a multipack, can't be sold separately.
Ni namenjen prodaji kot samostojna enota.
Amnesia, memory impairment, coordination abnormal/ataxia, paraesthesia, disturbance in attention
• amnezija (izguba spomina), oslabljen spomin (pozabljivost), poslabšana koordinacija/ataksija (motena usklajenost mišičnih gibov), parestezija (mravljinčenje), motnje pozornosti (izguba koncentracije)
Box of 20, 30, 50, 60, 80, 100, 120 multipack containing 200 (2 x 100) [with Blue Box]
Škatla z 20, 30, 50, 60, 80, 100, 120 skupno pakiranje, ki vsebuje 200 (2 x 100) [S PODATKI ZA t.i.
250 mg tablet: indigo carmine aluminum lake (E132), sunset yellow FCF aluminum lake (E110),
250 mg tableta: indigotin (E132), sončno rumeno FCF (E110), kinolinsko rumeno (E104) 500 mg tableta: kinolinsko rumeno (E104)
CLcr (ml/min/1.73 m
CLcr (ml/min/1,73 m koncentracija kreatinina v serumu (mg/dl)
Hyponatraemia
hiperkinezija (hiperaktivnost)
Box of 10, 20, 30, 50, 60, 100, 120 multipack containing 200 (2 x 100) [with Blue Box]
Škatla z 10, 20, 30, 50, 60, 100, 120 skupno pakiranje, ki vsebuje 200 (2 x 100) [S PODATKI ZA t.i.
Pancytopenia,neutropen ia, agranulocytosis
Bolezni krvi in limfatičnega sistema trombocitopenija levkopenija pancitopenija, nevtropenija, agranulocitoza
Aluminium/PVC/PE/PVDC blisters placed into cardboard boxes containing 20, 30, 50, 60, 80, 100, 120 and multipack containing 200 (2 packs of 100) film-coated tablets.
Zdravilo Matever 750 mg filmsko obložene tablete je na voljo v pretisnih omotih aluminij/ PVC/PE/PVDC, v škatlah z 20, 30, 50, 60, 80, 100, 120 in skupnem pakiranju, ki vsebuje 200 (2 pakiranji po 100) filmsko obloženih tablet.
Box of 10, 20, 30, 50, 60, 100 multipack containing 200 (2 x 100) [with Blue Box]
Škatla z 10, 20, 30, 50, 60, 100 skupno pakiranje, ki vsebuje 200 (2 x 100) [S PODATKI ZA t.i.
Box of 20, 30, 50, 60, 100 multipack containing 200 (2 x 100) [with Blue Box]
Škatla z 20, 30, 50, 60, 100 skupno pakiranje, ki vsebuje 200 (2 x 100) [S PODATKI ZA t.i.
Aluminium/PVC/PE/PVDC blisters placed into cardboard boxes containing 10, 20, 30, 50, 60, 100, 120 and multipack containing 200 (2 packs of 100) film-coated tablets.
Zdravilo Matever 500 mg filmsko obložene tablete je na voljo v pretisnih omotih aluminij/ PVC/PE/PVDC, v škatlah z 10, 20, 30, 50, 60, 100, 120 in skupnem pakiranju, ki vsebuje 200 (2 pakiranji po 100) filmsko obloženih tablet.
Pharmathen S.A. Tel.: +30 210 66 04 300
Deutschland Pharmathen S.A Tel.: +30 210 66 04 300
Aluminium/PVC/PE/PVDC blisters placed into cardboard boxes containing 10, 20, 30, 50, 60, 100 and multipack containing 200 (2 packs of 100) film-coated tablets.
Zdravilo Matever 1000 mg filmsko obložene tablete je na voljo v pretisnih omotih aluminij/ PVC/PE/PVDC, v škatlah z 10, 20, 30, 50, 60, 100 in skupnem pakiranju, ki vsebuje 200 (2 pakiranji po 100) filmsko obloženih tablet.
Aluminium/PVC/PE/PVDC blisters placed into cardboard boxes containing 20, 30, 50, 60, 100 and multipack containing 200 (2 packs of 100) film-coated tablets.
Zdravilo Matever 250 mg filmsko obložene tablete je na voljo v pretisnih omotih aluminij/ PVC/PE/PVDC, v škatlah z 20, 30, 50, 60, 100 in skupnem pakiranju, ki vsebuje 200 (2 pakiranji po 100) filmsko obloženih tablet.
Coating agent (yellow) consisting of: Hydroxypropylcellulose (E463) Hypromellose (E464) Propylene glycol (E1520) Quinoline yellow aluminium lake (E104) Sorbic acid (E200)
Obloga (rumena), ki jo sestavljajo: hidroksipropilceluloza (E463), hipromeloza (E464), propilenglikol (E1520), kinolinsko rumeno (E104), sorbinska kislina (E200), sorbitan monooleat (E494), titanov dioksid (E171), vanillin.
Talk to your doctor before you are given Matever
Pred začetkom jemanja zdravila Matever se posvetujte s svojim zdravnikom
The capsules should be taken with food, preferably at the same time every day.
Kapsule je treba vzeti s hrano, najbolje vsak dan ob istem času.
It is available as capsules (4 and 8 mg).
Na voljo je v kapsulah (4 in 8 mg).
The patients rated the severity of their symptoms themselves.
Bolniki so resnost simptomov ocenili sami.
The European Commission granted a marketing authorisation valid throughout the European Union for Silodyx on 29 January 2010.
Evropska komisija je dovoljenje za promet z zdravilom Silodyx, veljavno po vsej Evropski uniji, izdala dne 29. januarja 2010.
They should be swallowed whole, preferably with a glass of water.
Pogoltniti jih je treba cele, najbolje s kozarcem vode.
For men with moderate kidney problems, the starting dose should be 4 mg once a day.
Pri moških z zmernimi težavami z ledvicami mora biti začetni odmerek 4 mg enkrat dnevno.
The full EPAR for Silodyx can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Silodyx je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This is a summary of the European public assessment report (EPAR) for Silodyx.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Silodyx.
The recommended dose is one 8 mg capsule once a day.
Priporočeni odmerek je ena 8-miligramska kapsula enkrat dnevno.
This may be increased to 8 mg once a day after a week.
Po enem tednu ga je mogoče povečati na 8 mg enkrat dnevno.
The main measure of effectiveness in all three studies was the improvement of the patients' international prostate symptom score (IPSS) after 12 weeks of treatment.
Glavno merilo učinkovitosti v vseh treh študijah je bilo izboljšanje ocene IPSS (International Prostate Symptom Score) pri bolnikih po 12 tednih zdravljenja.
What measures are being taken to ensure the safe and effective use of Silodyx?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Silodyx?
The effects of Silodyx were first tested in experimental models before being studied in humans.
Učinki zdravila Silodyx so bili najprej preskušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
In the two studies where Silodyx was compared only with placebo, the IPSS was around 21 points at the start of the study.
V dveh študijah, v katerih so zdravilo Silodyx primerjali le s placebom, je bila ocena IPSS na začetku študije približno 21 točk.
A risk management plan has been developed to ensure that Silodyx is used as safely as possible.
Za zagotovitev čim varnejše uporabe zdravila Silodyx je bil pripravljen načrt obvladovanja tveganj.
After 12 weeks, it had fallen by around 6.4 points in the men who took Silodyx, and by around 3.5 points in the men who took placebo.
Po 12 tednih se je zmanjšala za približno 6,4 točke pri moških, ki so jemali zdravilo Silodyx, in za približno 3,5 točke pri moških, ki so jemali placebo.
For more information about treatment with Silodyx, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Solodyx preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The CHMP decided that Silodyx's benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Silodyx večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
Silodyx is not recommended for patients with severe kidney problems.
Zdravilo Silodyx ni priporočeno za bolnike s hudimi težavami z ledvicami.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Silodyx.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Silodyx, including the appropriate precautions to be followed by healthcare professionals and patients.
V skladu s tem načrtom so bile v povzetek glavnih značilnosti tega zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
In the third study, IPSS was around 19 points before treatment, falling by 7.0 points in the men who took Silodyx after 12 weeks, 6.7 points in the men who took tamsulosin and 4.7 points in the men who took placebo.
V tretji študiji je bila ocena IPSS pred zdravljenjem približno 19 točk, po 12 tednih je pri moških, ki so jemali zdravilo Silodyx, padla za 7,0 točke, pri moških, ki so jemali tamsulozin, za 6,7 točke, pri tistih, ki so jemali placebo, pa za 4,7 točke.
IPSS is a rating of the patient's symptoms such as the inability to empty the bladder, and the urge to urinate repeatedly or to strain while urinating.
IPSS je ocena bolnikovih simptomov, kot so nezmožnost praznjenja mehurja, potreba po pogostem mokrenju ali napenjanje med mokrenjem.
When enlarged, it can cause problems with the flow of urine.
Če je povečana, lahko povzroča težave pri izločanju seča.
The most common side effect with Silodyx (seen in more than 1 patient in 10) is a reduction in the amount of semen released during ejaculation.
Najpogostejši neželeni učinek zdravila Silodyx (opažen pri več kot 1 bolniku od 10) je zmanjšanje količine sperme, izločene med ejakulacijo.
For the full list of all side effects and restrictions with Silodyx, see the package leaflet.
Za celoten seznam vseh neželenih učinkov in omejitev pri uporabi zdravila Silodyx glejte navodilo za uporabo.
It works by blocking receptors called alpha1A adrenoreceptors in the prostate gland, the bladder and the urethra (the tube that leads from the bladder to the outside of the body).
Deluje tako, da zavira receptorje, imenovane adrenergični receptorji alfa 1A, v prostati, mehurju in sečnici (cevki, ki vodi od mehurja ven iz telesa).
The prostate gland is an organ found at the base of the bladder in men.
Prostata je organ, ki se nahaja pod mehurjem pri moških.
By blocking these receptors, silodosin allows these muscles to relax, making it easier to pass urine and relieving the symptoms of BPH.
Z zaviranjem teh receptorjev silodozin omogoča sprostitev teh mišic, kar olajša mokrenje in simptome BHP.
What benefit has Silodyx shown during the studies?
Kakšne koristi je zdravilo Silodyx izkazalo med študijami?
Other information about Silodyx
Druge informacije o zdravilu Silodyx
In addition, the company that makes Silodyx will ensure that eye surgeons are provided with information on IFIS in all Member States where the medicine will be marketed.
Poleg tega bo družba, ki izdeluje zdravilo Silodyx, zagotovila, da bodo v vseh državah članicah, v katerih bo zdravilo na trgu, očesni kirurgi seznanjeni z možnostjo pojava medoperacijskega sindroma ohlapne šarenice (IFIS).
Silodyx is a medicine that contains the active substance silodosin.
Silodyx je zdravilo, ki vsebuje zdravilno učinkovino silodozin.
One of these studies also compared Silodyx with tamsulosin (another medicine used for BPH).
V eni izmed teh študij so zdravilo Silodyx primerjali tudi s tamsulozinom (drugim zdravilom za zdravljenje BHP).
The active substance in Silodyx, silodosin, is an alpha adrenoreceptor antagonist.
Zdravilna učinkovina zdravila Silodyx, silodozin, je antagonist adrenergičnih receptorjev alfa.
Silodyx is used to treat the symptoms of benign prostatic hyperplasia (BPH, an enlarged prostate gland) in adults.
Zdravilo Silodyx se uporablja za zdravljenje simptomov benigne hiperplazije prostate (BHP, povečana prostata) pri odraslih.
Silodyx has been compared with placebo (a dummy treatment) in three main studies involving over 1,800 men with BPH.
Zdravilo Silodyx so primerjali s placebom (zdravilom brez zdravilne učinkovine) v treh glavnih študijah, ki so vključevale več kot 1 800 moških z BHP.
Intra operative floppy iris syndrome (IFIS) occurs in some patients taking alpha adrenoreceptor antagonists and may lead to complications during cataract surgery.
Medoperacijski sindrom ohlapne šarenice (IFIS) se pojavi pri nekaterih bolnikih, ki jemljejo antagoniste adrenergičnih receptorjev, in lahko privede do zapletov med operacijo sive mrene.
When these receptors are activated, they cause the muscles controlling the flow of urine to contract.
Ko so ti receptorji aktivirani, povzročijo stiskanje mišic, ki nadzorujejo izločanje seča.
What is the risk associated with Silodyx?
Kakšna tveganja so povezana z zdravilom Silodyx?
Silodyx was more effective than placebo and as effective as tamsulosin at reducing symptoms of BPH.
Zdravilo Silodyx je bilo pri lajšanju simptomov BHP učinkovitejše od placeba in enako učinkovito kot tamsulozin.
Why has Silodyx been approved?
Zakaj je bilo zdravilo Silodyx odobreno?
IFIS is a condition that makes the iris floppy.
IFIS povzroči ohlapno šarenico.
How has Silodyx been studied?
Kako je bilo zdravilo Silodyx raziskano?
What is Silodyx used for?
Za kaj se zdravilo Silodyx uporablja?
What is Silodyx?
Kaj je zdravilo Silodyx?
How does Silodyx work?
Kako zdravilo Silodyx deluje?
How is Silodyx used?
Kako se zdravilo Silodyx uporablja?
MA (EU) Numbers
Številka (EU) dovoljenja za promet
ANNEX IV
DODATEK IV
• Conduct a drug utilisation study (DUS) to monitor the effectiveness of the risk minimisation measures.
• izvedba študije o uporabi zdravila za spremljanje učinkovitosti ukrepov za zmanjševanje tveganja.
The National Competent Authorities, coordinated by the Reference Member State, shall ensure that the following conditions are fulfilled by the Marketing Authorisation Holders:
Pristojni nacionalni organi, ki jih usklajuje referenčna država članica, zagotovijo, da imetniki dovoljenj za promet z zdravili izpolnijo naslednje pogoje:
The protocol and the timelines of the DUS should be provided to the RMS within one month of the commission decision concluding this referral procedure.
Protokol in časovni načrt študije je treba predložiti referenčni državi članici v enem mesecu po odločbi Komisije, s katero se zaključi ta napotitev;
• Shorten the PSUR cycle to an annual submission
• skrajšanje cikla PSUR na letno oddajo.
• Circulate the DHPC agreed upon with the CHMP, in accordance with the agreed communication plan.
• po dogovoru s CHMP razdeljevanje neposrednih obvestil za zdravstvene delavce v skladu s sprejetim komunikacijskim načrtom;
Sildenafil ratiopahrm EMA/432244/2013
Sildenafil ratiopharm EMA/432233/2013
The full EPAR for Sildenafil ratiopharm can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Sildenafil ratiopharm je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This is a summary of the European public assessment report (EPAR) for sildenafil.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo sildenafil.
What are the benefits and risks of sildenafil?
Kakšne so koristi in tveganja, povezani z zdravilom sildenafil?
The European Commission granted a marketing authorisation valid throughout the European Union for Sildenafil ratiopharm on 23 December 2009.
Evropska komisija je dovoljenje za promet z zdravilom Sildenafil ratiopharm, veljavno po vsej Evropski uniji, odobrila dne 23. decembra 2009.
For more information about treatment with sildenafil, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom sildenafil preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Sildenafil ratiopharm is used to treat adult men with erectile dysfunction (sometimes called impotence), when they cannot get or keep a sufficiently hard penis (erection) for satisfactory sexual activity.
Zdravilo Sildenafil ratiopharm se uporablja za zdravljenje erektilne disfunkcije (imenovane tudi impotenca) pri odraslih moških, kadar ne zmorejo doseči ali ohraniti dovolj čvrstega penisa (erekcije) za zadovoljivo spolno dejavnost.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for sildenafil.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
The recommended dose of Sildenafil ratiopharm is 50 mg taken as needed about one hour before sexual activity.
Priporočeni odmerek zdravila Sildenafil ratiopharm je 50 mg, ki se vzame po potrebi približno eno uro pred spolnim odnosom.
liver function or severely reduced kidney function should start treatment with the 25-mg dose.
jeter ali močno zmanjšanim delovanjem ledvic morajo zdravljenje začeti s 25-miligramskim odmerkom.
Sexual stimulation is still needed to produce an erection.
Kljub temu je za erekcijo še vedno potrebno spolno vzburjenje.
This means that Sildenafil ratiopharm is similar to a ‘reference medicine' already authorised in the European Union (EU) called Viagra.
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Viagra.
Because Sildenafil ratiopharm is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.
Ker je zdravilo Sildenafil ratiopharm generično zdravilo in je biološko enakovredno referenčnemu zdravilu, velja, da so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
The CHMP concluded that, in accordance with EU requirements, Sildenafil ratiopharm has been shown to have comparable quality and to be bioequivalent to Viagra.
CHMP je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Sildenafil ratiopharm primerljivo raven kakovosti kot zdravilo Viagra ter da mu je biološko enakovredno.
Sildenafil ratiopharm is a ‘generic medicine'.
Sildenafil ratiopharm je „generično zdravilo“.
The dose may be increased to a maximum of 100 mg or decreased to 25 mg depending on the effectiveness and side effects.
Odmerek zdravila se lahko glede na učinkovitost in neželene učinke poveča na največ 100 mg ali zmanjša na 25 mg. Bolniki z zmanjšanim delovanjem
The active ingredient in Sildenafil ratiopharm, sildenafil, belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors.
Zdravilna učinkovina v zdravilu Sildenafil ratiopharm, sildenafil, spada v skupino zdravil, imenovanih zaviralci fosfodiesteraze tipa 5 (PDE5).
Other information about sildenafil
Druge informacije o zdravilu sildenafil:
Because Sildenafil ratiopharm is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Viagra.
Ker je zdravilo Sildenafil ratiopharm generično zdravilo, so bile študije na bolnikih omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Viagra.
What is sildenafil?
Kaj je sildenafil?
Sildenafil ratiopharm is a medicine that contains the active substance sildenafil.
Sildenafil ratiopharm je zdravilo, ki vsebuje zdravilno učinkovino sildenafil.
The Committee recommended that Sildenafil ratiopharm be given marketing authorisation.
Priporočil je, da se za zanj odobri dovoljenje za promet.
Why has sildenafil been approved?
Zakaj je bilo zdravilo sildenafil odobreno?
If Sildenafil ratiopharm is taken with food, the onset of activity may be delayed compared with taking Sildenafil ratiopharm without food.
Če se zdravilo Sildenafil ratiopharm zaužije sočasno s hrano, lahko začne delovati pozneje, kot če se zaužije brez nje.
By blocking the breakdown of cGMP, Sildenafil ratiopharm restores erectile function.
Zdravilo Sildenafil ratiopharm z zaviranjem razgradnje cGMP ponovno vzpostavi erektilno funkcijo.
How has sildenafil been studied?
Kako je bilo zdravilo sildenafil raziskano?
What is sildenafil used for?
Za kaj se zdravilo sildenafil uporablja?
How is sildenafil used?
Kako se zdravilo sildenafil uporablja?
How does sildenafil work?
Kako zdravilo sildenafil deluje?
Treatment with Abseamed is divided into two stages - correction and maintenance phase.
Zdravljenje z zdravilom Abseamed poteka v dveh fazah - korekcijska in vzdrževalna faza.
• a swollen face, lips, mouth, tongue or throat,
• otekanje obraza, ustnic, ust, jezika ali grla,
Your doctor will monitor your blood pressure regularly while you are using Abseamed.
Zdravnik bo redno nadziral vaš krvni tlak, medtem ko uporabljate zdravilo Abseamed.
Abseamed should not be used and discarded - if the liquid is coloured or you can see particles floating in it, - if the seal is broken, - if you know, or think that it may have been accidentally frozen, or - if there has been a refrigerator failure.
Zdravila Abseamed se ne sme uporabiti in ga je treba zavreči: - če je tekočina obarvana ali v njej vidite plavati delce, - če je tesnilo poškodovano, - če veste ali mislite, da je bila raztopina pomotoma zamrznjena ali - če hladilnik ni pravilno deloval.
Abseamed has no or negligible influence on the ability to drive and use machines.
Zdravilo Abseamed nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Abseamed should be administered after the completion of the blood donation procedure.
Zdravilo Abseamed je treba uporabiti po tem, ko je postopek darovanja krvi končan.
• For adults and children Abseamed is given as an injection either into a vein (intravenously) or a tube that goes into a vein.
• Odraslim in otrokom se daje zdravilo Abseamed v obliki injekcije bodisi v veno (intravensko) ali s cevko, ki gre v veno.
Medice Arzneimittel Pütter GmbH & Co. KG, Kuhloweg 37, D-58638 Iserlohn, Germany
Medice Arzneimittel Pütter GmbH & Co KG, Kuhloweg 37, D-58638 Iserlohn, Nemčija